Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

The rise of GLP-1s has made treat­ing obe­si­ty one of the largest mar­ket op­por­tu­ni­ties in his­to­ry. It al­so has re­in­forced a detri­men­tal re­la­tion­ship be­tween phys­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER